Plasma concentrations and clearance of procalcitonin during continuous veno-venous hemofiltration in septic patients. 2001

M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
Department of Anaesthesiology, University of Jena, Germany.

We determined the elimination characteristics of procalcitonin (PCT) during continuous veno-venous hemofiltration (CVVHF) and the resulting effect on PCT plasma levels. A prospective study was conducted in patients with sepsis and acute oliguric renal failure, treated with CVVHF using a polysulfone membrane (Baxter Renaflo II PSHF 1200). Patients had sepsis and PCT plasma levels > 4 ng ml(-1) (n = 26). PCT was measured in the pre- and post-filter plasma and the ultrafiltrate at 0, 5, 10, and 15 min and 1, 2, 4, 6, 12, and 24 h after setup of CVVHF. PCT sieving coefficient was 0.24. Elimination of PCT, however, depended on the duration of filtration, because filter adsorption was the main mechanism of PCT clearance during the first hour of hemofiltration, finally increasing to a clearance of PCT into the ultrafiltrate of 2.8-5.5 mL/min after 2 h. PCT plasma levels were not significantly altered during CVVHF (96% of the initial concentration after 24 h, P = 0.72). Similar to what has been observed with cytokines and other proteins of a comparable molecular weight, PCT is removed from the plasma during CVVHF, but plasma PCT levels are unchanged. Thus, PCT can be used as a diagnostic parameter even in patients with acute renal failure undergoing CVVHF.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011498 Protein Precursors Precursors, Protein
D002116 Calcitonin A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults. Thyrocalcitonin,Calcitonin(1-32),Calcitrin,Ciba 47175-BA,Eel Calcitonin,Calcitonin, Eel,Ciba 47175 BA,Ciba 47175BA
D005260 Female Females
D006440 Hemofiltration Extracorporeal ULTRAFILTRATION technique without HEMODIALYSIS for treatment of fluid overload and electrolyte disturbances affecting renal, cardiac, or pulmonary function. Arteriovenous Hemofiltration,Venovenous Hemofiltration,Arteriovenous Hemofiltrations,Hemofiltration, Arteriovenous,Hemofiltration, Venovenous,Hemofiltrations,Venovenous Hemofiltrations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015740 Calcitonin Gene-Related Peptide A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator. Calcitonin Gene-Related Peptide I,Calcitonin Gene-Related Peptide II,alpha-CGRP,alpha-Calcitonin Gene-Related Peptide,beta-CGRP,beta-Calcitonin Gene-Related Peptide,Calcitonin Gene Related Peptide,Calcitonin Gene Related Peptide I,Calcitonin Gene Related Peptide II,Gene-Related Peptide, Calcitonin,alpha Calcitonin Gene Related Peptide,beta Calcitonin Gene Related Peptide
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control

Related Publications

M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
October 2008, Intensive care medicine,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
April 1998, The International journal of artificial organs,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
December 1991, Nihon rinsho. Japanese journal of clinical medicine,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
October 1999, Intensive care medicine,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
July 2008, Intensive care medicine,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
January 2008, ASAIO journal (American Society for Artificial Internal Organs : 1992),
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
April 1991, Critical care medicine,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
October 1991, Minerva anestesiologica,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
February 2001, Intensive care medicine,
M Meisner, and E Hüttemann, and T Lohs, and L Kasakov, and K Reinhart
June 1990, Critical care medicine,
Copied contents to your clipboard!